Open AccessBrief Report
Author(s) -
Joel E. Gallant,
Ellen Koenig,
Jaime Andrade-Villanueva,
Ploenchan Chetchotisakd,
Edwin DeJesus,
Francisco Antúnes,
Keikawus Arastéh,
Giuliano Rizzardini,
Jan Fehr,
Hui C. Liu,
Michael E. Abram,
Huyen Cao,
Javier Szwarcberg
Publication year - 2015
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000000598
Subject(s) - cobicistat , atazanavir , emtricitabine , ritonavir , discontinuation , medicine , elvitegravir , lopinavir , gastroenterology , pharmacology , human immunodeficiency virus (hiv) , viral load , virology , antiretroviral therapy
Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.